Mercedes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3451329/publications.pdf

Version: 2024-02-01

26 papers	1,053 citations	430874 18 h-index	552781 26 g-index
26 all docs	26 docs citations	26 times ranked	1908 citing authors

#	Article	IF	Citations
1	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. European Urology, 2021, 79, 722-733.	1.9	17
2	Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes. Cancers, 2021, 13, 4960.	3.7	7
3	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 594023.	2.8	7
4	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. Cells, 2020, 9, 203.	4.1	15
5	Plasma AR status and cabazitaxel in heavilyÂtreated metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 116, 158-168.	2.8	29
6	The influence of treatment sequence in the prognostic value of TMPRSS2â€ERG as biomarker of taxane resistance in castrationâ€resistant prostate cancer. International Journal of Cancer, 2019, 145, 1970-1981.	5.1	13
7	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. BMC Medicine, 2019, 17, 8.	5.5	28
8	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 368-373.	1.9	64
9	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. British Journal of Cancer, 2017, 117, 1777-1786.	6.4	58
10	Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. Clinical Genitourinary Cancer, 2016, 14, 265-270.	1.9	18
11	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 709-713.	1.9	63
12	The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation. PLoS ONE, 2015, 10, e0129661.	2.5	34
13	Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. Oncotarget, 2015, 6, 10604-10616.	1.8	21
14	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Molecular Cancer, 2014, 13, 237.	19.2	60
15	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 1270-1284.	4.1	131
16	Nuclear factorâ€kappa B and interleukinâ€6 related docetaxel resistance in castrationâ€resistant prostate cancer. Prostate, 2013, 73, 512-521.	2.3	52
17	Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2012, 11, 329-339.	4.1	92
18	Utility of Urothelial mRNA Markers in Blood for Staging and Monitoring Bladder Cancer. Urology, 2012, 79, 240.e9-240.e15.	1.0	17

#	Article	IF	Citations
19	Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?. BJU International, 2012, 110, 1310-1316.	2.5	21
20	Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study. Cancer Biology and Therapy, 2011, 11, 177-183.	3.4	8
21	Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma. Clinical Cancer Research, 2010, 16, 2624-2633.	7.0	70
22	Multiplex preamplification of specific cDNA targets prior to gene expression analysis by TaqMan Arrays. BMC Research Notes, 2008, 1, 21.	1.4	31
23	Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival. European Urology, 2008, 54, 1363-1372.	1.9	40
24	Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genetics and Cytogenetics, 2007, 173, 131-135.	1.0	31
25	Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. European Urology, 2007, 51, 409-415.	1.9	73
26	Clinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-GuÃ©rin Therapy. European Urology, 2007, 52, 752-759.	1.9	53